For the Quarter Ending September 2025
North America
• In the United States, the Piperacillin Tazobactam Price Index rose in Q3 2025, driven by escalating production costs.
• Rising input materials, energy, and transportation costs increased Piperacillin Tazobactam production expenses in Q3 2025.
• Demand for chemicals, including Piperacillin Tazobactam, deteriorated in Q3 2025, with new orders falling.
• US chemical manufacturing activity contracted in Q3 2025, with industrial production showing marginal 0.1% YoY growth.
• In August 2025, PPI rose 2.6% YoY, indicating higher raw material costs for Piperacillin Tazobactam manufacturers.
• In September 2025, CPI rose 3.0% YoY, signaling increased operational and transportation costs for producers.
• US pharmaceutical product exports increased between July and August 2025, while imports decreased.
• A strong 5.42% YoY increase in retail sales in September 2025 supported a stable healthcare funding environment.
• The low unemployment rate of 4.3% in September 2025 supported consistent demand for healthcare services.
Why did the price of Piperacillin Tazobactam change in September 2025 in North America?
• Increased input and raw material costs for chemical manufacturers elevated production expenses in Q3 2025.
• Energy (fuel & power) and transportation costs for chemical manufacturers rose during Q3 2025.
• Major customer market demand for chemicals deteriorated, and new orders fell in Q3 2025.
APAC
• In China, the Piperacillin Tazobactam Price Index rose quarter-over-quarter in Q3 2025, driven by elevated raw material costs.
• Production costs for Piperacillin Tazobactam increased in Q3 2025 due to rising Penicillin G Sodium expenses.
• The Piperacillin Tazobactam Price Forecast suggests upward pressure from constrained raw material supply and elevated import costs.
• Pharmaceutical product demand was bolstered by an increasing geriatric population and chronic diseases in 2025.
• China's Consumer Price Index decreased 0.3% year-on-year in September 2025, reflecting deflationary trends.
• The Producer Price Index decreased 2.3% year-on-year in September 2025, impacting factory-gate prices.
• Industrial production increased 6.5% year-on-year in September 2025, supporting manufacturing activity.
• The Manufacturing Index was contracting in September 2025, indicating a broader industrial slowdown.
• Retail sales grew 3.0% year-on-year in September 2025, suggesting stable consumer demand.
Why did the price of Piperacillin Tazobactam change in September 2025 in APAC?
• Penicillin G Sodium procurement costs were elevated in Q3 2025.
• Regional Penicillin G Sodium supply tightened due to August 2025 maintenance shutdowns.
• Pharmaceutical raw material imports faced elevated costs in Q3 2025 from tariffs and freight.
Europe
• In Germany, the Piperacillin Tazobactam Price Index experienced downward pressure in Q3 2025, influenced by a -1.7% PPI YoY in September 2025.
• Piperacillin Tazobactam production costs remained persistently high in Q3 2025, despite a -1.7% PPI YoY in September 2025.
• Global antibiotic supplies faced considerable stress in 2025 due to API shortages and logistical issues in July 2025.
• Germany's pharmaceutical market expanded in Q3 2025, driven by an aging population and demand for high-value therapies.
• Manufacturing Index showed a contracting trend in September 2025, with industrial production declining by -1.0% YoY.
• Elevated energy costs for Germany's industrial sector in Q3 2025 impacted overall production expenses.
• A 2.4% CPI YoY in September 2025 signaled higher operational costs for Piperacillin Tazobactam manufacturers.
• Inventories of some chemical raw materials tightened by the end of Q3 2025, affecting supply stability.
Why did the price of Piperacillin Tazobactam change in September 2025 in Europe?
• API prices surged in July 2025 due to logistical challenges and increased freight costs.
• Producer prices experienced downward pressure in Q3 2025, with a -1.7% PPI YoY in September 2025.
• Overall production costs remained persistently high in Q3 2025, influenced by elevated energy costs.
For the Quarter Ending December 2022
North America
The price of Piperacillin & Tazobactam witnessed an assorted trend in the North American market throughout the fourth quarter of 2022. Fluctuating demand from the downstream pharmaceutical and healthcare sector pulled back the prices of Piperacillin & Tazobactam in the regional market. Many retailers of Piperacillin & Tazobactam encountered the opposite issue in Q4.
They had too many stocks on hand following months of COVID supply chain shocks and headlines about empty shelves. After COVID, purchaser preferences changed, and supply chain issues were eased because of reduced shipping demand brought on by slower consumer spending and a fall in manufacturing activity in December. All these factors resulted in the mixed price trend of Piperacillin & Tazobactam in the US domestic market.
Asia- Pacific
In the Asia-Pacific region, Piperacillin & Tazobactam prices achieved robust gains with the start of the fourth quarter of 2022. The Ex-Vapi prices for Piperacillin & Tazobactam in India increased by 1.8% in October. As in the first week of October, the Long week holiday affected the production activities in factories resulting in tight supply in the domestic market. However, the prices in India started to follow a downtrend and decreased by around 1.8% in the second half of the quarter. Covid cases resurgence from the end of October led to both logistic restriction and end-user run rate limitation, which resulted in Piperacillin & Tazobactam inventory accumulation and lower offers. The impact of the epidemic ebbed away the demand, leading to some manufacturers opting to slow production. Additionally, export orders from the international market were sluggish due to dull market dynamics.
Europe
During the fourth quarter of 2022, Piperacillin & Tazobactam prices fluctuated in the European market, mirroring the price pattern in the Asian and North American markets. The presence of inquiries from the end-user pharmaceutical industry in H1 of Q4 raised the demand for the product in the local German market. Later, with the commencement of H2 of Q4, the prices depreciated in the European region, with demand scaling down its pace from the buyer's end. Furthermore, stockpiled inventories on the back of weak purchasing activities propelled domestic merchants to lower their Piperacillin & Tazobactam quotations to raise their orders, resulting in a declining price trend in Europe.
For the Quarter Ending September 2022
North America
Piperacillin & Tazobactam API prices showcased a downward trend in the US Market throughout the third quarter of 2022, backed by weak demand. The speculation of recession across the US market has dampened the queries from the downstream pharmaceutical industries. Furthermore, the domestic market participants had enough stocks to meet the overall requirements during the third quarter in the United States. From July, China's intermittent lockdowns and several Chinese manufacturing sites closed for maintenance resulting in curtailment in imports into the US, which substantially impacted the domestic market's dropping demand and downward pricing trend in the last weeks of the third quarter.
Asia- Pacific
The price trend for Piperacillin & Tazobactam API showed downward sentiments in the Asia Pacific market during the third quarter of 2022, with values declining from USD 111875/MT to USD 106703/MT from July to September in India. The factors influencing this pricing trend are the declining cost of raw materials, weakening consumer spending, and weak end-user sector demand. Big suppliers only placed orders for immediate use due to steady offtakes and weak downstream demand. However, after the markets began operations in the last week of July, several manufacturing facilities carried out maintenance, which reduced the amount of product that was accessible to local as well as international providers.
Europe
The market of Piperacillin & Tazobactam API mimics a similar price trajectory as in North America during the third quarter of 2022 in the European Region. The slow offtakes and weak purchasing activities from pharma producers, supported by lessening demand from end-user industries, were factors behind the decline in Germany. However, the market participants were left with enough stock to cater to the overall order. Additionally, fluctuations in trade frequency from exporting countries like India and China during the whole quarter also affected the market value of Piperacillin & Tazobactam API. Therefore, traders were ready to bargain over the purchases as fear of recession loomed from late August to the last week of September.
For the Quarter Ending June 2022
North America
In North America, the Piperacillin & Tazobactam API market remained consolidated in the second quarter of 2022, as the domestic market showcased a higher requirement. Supply chain disruption by China left manufacturers in the United States with inadequate supply. The price escalation was also due to high freight costs amid surging crude prices. The robust market of upstream Penicillin throughout the period also impacted the price trend. Also, North America led the Piperacillin & Tazobactam API market because of the rising demand from the downstream pharmaceutical industries. In addition, superior healthcare infrastructure facilities in these nations aided North American Piperacillin & Tazobactam API market expansion.
Asia- Pacific
Piperacillin & Tazobactam API market showcased unfavorable sentiments throughout the second quarter of 2022. In the Indian market, the prices of Piperacillin & Tazobactam API declined by 11.7% till June due to adequate supply and decreased demand from domestic and foreign markets. From March end, manufacturers could not work towards uplifting the market due to lower requirements; the overall market was on the downside. The Ex-Vapi prices of Piperacillin & Tazobactam plunged to INR 9400000/MT by the end of June across the Indian market due to the lower need for Piperacillin & Tazobactam injection from end-user pharmaceutical industries.
Europe
In the European region, the prices of Piperacillin & Tazobactam API dropped significantly in the second quarter of 2022 due to unfavorable market sentiments. In April and May, Piperacillin & Tazobactam prices plunged amidst sluggish buying and the availability of low imports. Piperacillin & Tazobactam prices have fallen amid slow trading activity, import pressure, and inexpensive raw materials. Weak demand, customer destocking, and competitive import prices continued to drag down European Piperacillin & Tazobactam. In June, the Piperacillin & Tazobactam API market in Europe showcased an increase on the back of improving demand with limited regional supply. In addition, the continued port congestions and increased freight charges caused supply chain disruption, prompting better market sentiments for Piperacillin & Tazobactam.
